Human Trials

Takeda’s Alunbrig improves PFS in phase 3 lung cancer trial

Takeda’s lung cancer drug Alunbrig (brigatinib) has significantly improved progression-free survival (PFS) in phase 3 ALTA-1L (ALK in lung cancer trial of AP26113 in 1st line) trial.

Chi-Med starts phase Ib/II trial of sulfatinib in NET and BTC patients

Hutchison China MediTech (Chi-Med) has commenced a phase Ib/II proof-of-concept study in the US to evaluate its small molecule angio-immuno kinase inhibitor sulfatinib in pancreatic neuroendocrine tumors (NET) and biliary tract cancer (BTC).

Leap Therapeutics to evaluate TRX518/avelumab combo for advanced solid tumors

Leap Therapeutics has signed a deal to evaluate its immuno-oncology compound TRX518 in combination with Merck and Pfizer’s avelumab, and chemotherapy for the treatment of advanced solid tumors.

Boehringer, Lilly diabetes drug Tradjenta succeeds in cardiovascular outcome trial

Boehringer Ingelheim and Eli Lilly and Company reported that the CARMELINA cardiovascular outcome trial evaluating their diabetes drug Tradjenta met its primary endpoint.

Pfizer, Lilly’s osteoarthritis pain drug meets co-primary endpoints in phase 3 study

Pfizer and Eli Lilly’s osteoarthritis (OA) pain drug, tanezumab, has met all three co-primary endpoints in a phase 3 study.

Roche’s baloxavir marboxil succeeds in phase III flu study

A phase III CAPSTONE-2 study has demonstrated that baloxavir marboxil reduced symptoms in people at high risk of complications from the flu.

Zynerba halts development of THC prodrug ZYN001

A failure in a phase 1 clinical program has forced Zynerba Pharmaceuticals to stop development of ZYN001, its pro-drug of tetrahydrocannabinol (THC) intended for the treatment of neuropsychiatric disorders including Tourette Syndrome.

Anavex gets approval to begin phase 2b/3 trial of Alzheimer’s disease treatment

Anavex Life Sciences has secured approval from the Australian Human Research Ethics Committee to begin its phase 2b/3 trial of Anavex 2-73 to treat early Alzheimer’s disease.

Lynparza delays disease progression in phase III trial for ovarian cancer

AstraZeneca and Merck have announced positive results from the randomised, double-blinded, placebo-controlled, Phase III SOLO-1 trial of Lynparza (olaparib) tablets.